Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
16 Oktoba 2021 10:47:37
Indomethacin kwa mjamzito
Indomethacin ni dawa jamii ya NSAID, inayotumika kwenye matibabu ya dalili za wastani na dalili kali za rheumatoid athraitiz, osteoarthraitiz, ankailozing spondilaitiz na maumivu makali ya bega kutokana na maambukizi kwenye kifuko cha maji au tendon.
Indomethacin hufanana na dawa zingine tatu jamii ya NSAID ambazo ni diclofenac, sulindac na tolmetin.
Matumizi ya indomethacin kipindi cha mwishoni mwa ujauzito huweza kuwa sumu kwa mtoto. Matumizi ya muda mfupi kama yale ya ndani ya masaa 24 hadi 48 tu hupunguza hatari hiyo.
Kutokana na taarifa za tafiti zilizofanyika kwa wanyama,zinaonyesha kuwa dawa zinazozuia uzalishaji wa prostaglandin ikiwa pamoja na indomethacin huweza kuzuia upandikizaji wa kiini mara baada ya uchavushaji kufanyika na hivyo kuzuia kuendelea kwa ujauzito.
Dawa jamii ya NSAID pia zimekuwa zikihusianishwa kusababisha kutoka kwa mimba na ulemavu wa kuzaliwa kwa watoto wa wamama waliotumia dawa hii kipindi cha kwanza cha ujauzito, licha ya hatari hiyo kuonekana kuwa ni ndogo.
Matumizi kwa mama mjamzito
Taarifa za binadamu zinaonyesha hatari kwenye kipindi cha kwanza na tatu cha ujauzito
Taarifa za binadamu zinaonyesha hatari kwenye kipindi cha kwanza na tatu cha ujauzito ina maana gani?
Ushahidi wa matumizi ya indomethacine na dawa zingine zinazofanana na indomethacin kwenye ujauzito zinaonekana kuwa ni sumu kwa ukuaji wa tumboni kwa na kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi cha kwanza na tatu tu cha ujauzito lakini si katika kipindi cha pili. Taarifa za madhara ya dawa hii kwa binadamu zinamashiko zaidi kuliko taarifa za tafiti kwa wanyama.
Matumizi kwa mama anayenyonyesha
Hakuna (zipo chache) taarifa za binadamu- Inaweze patana na unyonyeshaji
Hakuna (zipo chache) taarifa za binadamu- Inaweze patana na unyonyeshaji ina maana gani?
Hakuna taarifa za uzoefu kuhusu matumizi ya dawa hii kwa mama anayenyonyesha au kuna taarifa chache. Taarifa chache zilizopo zinaonyesha kuwa dawa hii haiwasilishi hatari yenye mashiko kwa kichanga anayenyonya maziwa ya mama anayetumia dawa.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
22 Aprili 2022 15:24:22
Rejea za mada hii:
1. Shepard TH. Catalog of Teratogenic Agents. 6th ed. Baltimore, MD: The Johns Hopkins University Press, 1989:348–9.
2. Montenegro MA, Palomino H. Induction of cleft palate in mice by inhibitors of prostaglandin synthesis. J Craniofac Genet Dev Biol 1990;10:83–94.
3. Moise KJ Jr, Ou C-N, Kirshon B, Cano LE, Rognerud C, Carpenter RJ Jr. Placental transfer of indomethacin in the human pregnancy. Am J Obstet Gynecol 1990;162:549–54.
3. Nielsen GL, Sorensen HT, Larsen H, Pedersen L. Risk of adverse birth outcome and miscarriage in pregnant users of nonsteroidal antiinflammatory drugs: population based observational study and case-control study. Br Med J 2001;322:266–70.
4. Ericson A, Kallen BAJ. Nonsteroidal antiinflammatory drugs in early pregnancy. Reprod Toxicol 2001;15:371–5.
5. Li DK, Liu L, Odouli R. Exposure to nonsteroidal antiinflammatory drugs during pregnancy and risk of miscarriage: population-based cohort study. Br Med J 2003;327:368–71.
6. Tassinari MS, Cook JC, Hurtt ME. NSAIDs and developmental toxicity. Birth Defects Res B Dev Reprod Toxicol 2003;68:3–4.
7. Atad J, David A, Moise J, Abramovici H. Classification of threatened premature labor related to treatment with a prostaglandin inhibitor: indomethacin. Biol Neonate 1980;37:291–6.
8. Gonzalez CHL, Jimenez PG, Pezzotti y R MA, Favela EL. Hipertension pulmonar persistente en el recien nacido por uso prenatal de inhibidores de las prostaglandinas (indometacina).
4. Informe de un caso. Ginecol Obstet Mex 1980;48:103–10.
9. Sureau C, Piovani P. Clinical study of indomethacin for prevention of prematurity. Eur J Obstet Gynecol Reprod Biol 1983;46:400–2.
10. Van Kets H, Thiery M, Derom R, Van Egmond H, Baele G. Perinatal hazards of chronic antenatal tocolysis with indomethacin. Prostaglandins 1979;18:893–907.
11. Van Kets H, Thiery M, Derom R, Van Egmond H, Baele G. Prostaglandin synthase inhibitors in preterm labor. Lancet 1980;2:693.
12. Blake DA, Niebyl JR, White RD, Kumor KM, Dubin NH, Robinson JC, Egner PG. Treatment of premature labor with indomethacin. Adv Prostaglandin Thromboxane Res 1980;8:1465–7.
13. Grella P, Zanor P. Premature labor and indomethacin. Prostaglandins 1978;16:1007–17.
14. Karim SMM. On the use of blockers of prostaglandin synthesis in the control of labor. Adv Prostaglandin Thromboxane Res 1978;4:301–6.
15. Katz Z, Lancet M, Yemini M, Mogilner BM, Feigl A, Ben Hur H. Treatment of premature labor contractions with combined ritodrine and indomethacine. Int J Gynaecol Obstet 1983;21:337–42
16. Niebyl JR, Blake DA, White RD, Kumor KM, Dubin NH, Robinson JC, Egner PG. The inhibition of premature labor with indomethacin. Am J Obstet Gynecol 1980;136:1014–9.
17. Peteja J. Indometacyna w zapobieganiu porodom przedwczesnym. Ginekol Pol 1980;51:347–53.
18. Reiss U, Atad J, Rubinstein I, Zuckerman H. The effect of indomethacin in labour at term. Int J Gynaecol Obstet 1976;14:369–74.
19. Souka AR, Osman N, Sibaie F, Einen MA. Therapeutic value of indomethacin in threatened abortion. Prostaglandins 1980;19:457–60.
20. Spearing G. Alcohol, indomethacin, and salbutamol. Obstet Gynecol 1979;53:171–4.
21. Chimura T. The treatment of threatened premature labor by drugs. Acta Obstet Gynaecol Jpn 1980;32:1620–4.
22. Suzanne F, Fresne JJ, Portal B, Baudon J. Essai therapeutique de l’indometacine dans les menaces d’accouchement premature: a propos de 30 observations. Therapie 1980;35:751–60.
23. Tinga DJ, Aranoudse JG. Postpartum pulmonary oedema associated with preventive therapy for premature labor. Lancet 1979;1:1026.
24. Dudley DKL, Hardie MJ. Fetal and neonatal effects of indomethacin used as a tocolytic agent.
5. Am J Obstet Gynecol 1985;151:181–4.
25. Gamissans O, Canas E, Cararach V, Ribas J, Puerto B, Edo A. A study of indomethacin combined with ritodrine in threatened preterm labor. Eur J Obstet Gynecol Reprod Biol 1978;8:123–8.
26. Wiqvist N, Lundstrom V, Green K. Premature labor and indomethacin. Prostaglandins 1975;10:515–26.
27. Wiqvist N, Kjellmer I, Thiringer K, Ivarsson E, Karlsson K. Treatment of premature labor by prostaglandin synthetase inhibitors. Acta Biol Med Germ 1978;37:923–30.
28. Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet Gynecol 1974;44:787–92.
29. Zuckerman H, Reiss U, Atad J, Lampert I, Ben Ezra S, Sklan D. The effect of indomethacin on plasma levels of prostaglandin F2α in women in labour. Br J Obstet Gynaecol 1977;84:339–43.
30. Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part I. J Perinat Med 1984;12:19–23.
31. Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II. Double-blind study. J Perinat Med 1984;12:25–9.
32. Niebyl JR. Prostaglandin synthetase inhibitors. Semin Perinatol 1981;5:274–87.
33. Niebyl JR, Witter FR. Neonatal outcome after indomethacin treatment for preterm labor. Am J Obstet Gynecol 1986;155:747–9.
34. Besinger RE, Niebyl JR, Keyes WG, Johnson TRB. Randomized comparative trial of 6. indomethacin and ritodrine for the long-term treatment of preterm labor. Am Obstet Gynecol 1991;164:981–8.
35. Evans DJ, Kofina AD, King K. Intraoperative amniocentesis and indomethacin treatment in the management of an immature pregnancy with completely dilated cervix. Obstet Gynecol 1992;79:881–2.
36. Leonardi MR, Hankins GDV. What’s new in tocolytics. Clin Perinatol 1992;19:367–84.
37. Higby K, Xenakis EM-J, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993;168:1247–59.
38. Morales WJ, Smith SG, Angel JL, O’Brien WF, Knuppel RA. Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study.